ロード中...
Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients
Dr Jordi Bruix* speaks to Laura Dormer, Editorial Director: Dr Jordi Bruix is the Head of the Barcelona Clinic Liver Cancer (BCLC) group at the Hospital Clinic (University of Barcelona, Spain) and Director of the Network for Research in Liver and Digestive Disease (CIBEREHD) in the Spanish Research...
保存先:
| 出版年: | Hepat Oncol |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Future Medicine Ltd
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095319/ https://ncbi.nlm.nih.gov/pubmed/30191039 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep-2016-0007 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|